Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, ORD_465342/2023, 16 June 2023)
| Date | 16 June 2023 |
|---|---|
| Court | CFI |
| Division | Paris (FR) Central Division - Seat |
| Type of action | Revocation Action |
| Registry reference | ORD_465342/2023 · UPC_CFI_80_2023 |
| Parties | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE v. HEALIOS K.K, OSAKA UNIVERSITY |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 16 June 2023, the presiding judge of panel 1 of the Paris Central Division referred to the Munich section the revocation action brought on 1 June 2023 by Astellas Institute for Regenerative Medicine against EP 3 056 564 B1, held by Healios K.K. and Osaka University (UPC_CFI_80/2023, ACT_465342/2023), which concerns the purification of retinal pigment epithelial cells. The order shows how actions are distributed between the seats of the Central Division: by the first IPC classification indicated on the patent.
Question
Which seat or section of the Central Division should hear a revocation action against a patent whose first classification falls within IPC section C?
Decision
Where a patent bears more than one classification, the action goes to the seat or section matching the first classification indicated, in line with Annex II to the Agreement (Rule 17.3 RoP, applied to the statement for revocation through Rule 47 RoP). Presidium decision PR/08052023 of 8 May 2023, in force since 1 June 2023, provisionally allocates section A to the Paris seat and section C to the Munich section until a further section of the Central Division is set up. As the patent’s first classification is C 12N 5/079, the Registry was instructed to refer the case, under Rule 345.3 RoP, to the presiding judge of the relevant panel of the Munich section. The order has no numbered paragraphs.
Key points for practice
- Practical point: the first IPC classification on the patent determines which seat of the Central Division hears the case, and an action lodged with another seat is referred to it.
Provisions applied
- Agreement on a Unified Patent Court
- Annex II, Statute, Art. 15(3)
- Rules of Procedure
- Rules 16 to 18, 17.3, 47 and 345.3
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Revocation action.
Publications by Matthieu Dhenne: G 1/25, Take Three: Anything You Leave in the Description May Be Used Against You (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- claimantASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE10 decisions in the corpusFollow this party
- defendantHEALIOS K.K5 decisions in the corpusFollow this party
- defendantOSAKA UNIVERSITY9 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Revocation Action
- Outcome (Dhenne Avocats summary)
- L'action en nullité est renvoyée à la section de Munich de la division centrale, la première classification CIB du brevet relevant de la section C.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 3 056 564mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 18 March 2024) cited in this record
- Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 20 November 2023) cited in this record
- Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 17 November 2023) cited in this record
- Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_CFI_80/2023, 11 October 2023) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 3 056 564 | Mentioned in the analysis (role not qualified) Also mentioned in 6 other decision(s): Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 23 Ju · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 18 Ma · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 20 No · Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 17 N · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_C · Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, ORD_ | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.